Clinical Trials in Neurodegenerative Diseases
Currently Recruiting:
Active, Not Recruiting:
Completed Studies:
The Phase 2 COG1201 ‘SHIMMER’ study enrolled 130 patients with mild-to-moderate dementia with Lewy bodies (DLB). Participants were randomized to receive one of two doses of the experimental candidate, CT1812, or placebo for six months. More information about SHIMMER can be found on clinicaltrials.gov under trial identifier NCT04735536.
On December 18, 2024, Cognition conducted a webcast to review findings from the SHIMMER study. An archive of the call and supporting materials may be found here.
The Phase 2 SHINE study recruited 153 individuals (50 to 85 years of age) who have mild-to-moderate Alzheimer’s disease. Participants were randomized to receive one of two doses of the experimental candidate, CT1812, or placebo for six months. More information may be found on clinicaltrials.gov under trial identifier NCT03507790.
On July 29, 2024, Cognition held a conference call to review topline findings from the SHINE study. An archive of the call and supporting materials may be found here. Cognition conducted a second call on October 30, 2024 to review findings of a pre-specified analysis of SHINE subgroups defined by their baseline plasma p-tau217 concentrations. An archive of this call and supporting materials may be found here.Â
SEQUEL
The Phase 2 COG0202 ‘SEQUEL’ study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of 16 patients with mild-to-moderate AD to evaluate the potential efficacy of CT1812 in restoring synaptic function in patients through qEEG measurement, as reflected by relative theta power. More information about SEQUEL can be found on clinicaltrials.gov under trial identifier NCT04735536.
On June 28, 2023, Cognition held a conference call to review findings from the SEQUEL study. An archive of the call and supporting materials may be found here.
SPARC
The Phase 1 COG0105 ‘SPARC’ study is a randomized, double-blind, placebo-controlled clinical trial of 23 patients with mild-to-moderate AD to evaluate CT1812 for safety and tolerability. Secondary objectives include the evaluation of potential effects of CT1812 on biologically relevant endpoints using various imaging modalities, including PET imaging and vMRI. More information about SPARC may be found on clinicaltrials.gov under trial identifier NCT03493282.Â
SNAP
The Phase 1 COG0104 ‘SNAP’ study was a randomized, double-blind, placebo-controlled clinical trial that enrolled three patients with mild-to-moderate AD to measure the effects of CT1812 on displacement of Aβ oligomers. More information about SPARC may be found on clinicaltrials.gov under trial identifier NCT03522129.
Additional Resource for Patients and their Families
Alzheimer's Disease
Dementia with Lewy Bodies
Geographic Atrophy
Clinical Trial Terminology
Before a novel product candidate can be approved, it must complete a rigorous clinical development process, which typically includes three distinct types of trials. Phase 1 clinical trials test experimental treatments at a variety of doses in healthy volunteers to understand how the candidate works in the human body and identify safety issues that may not have been apparent in preclinical research.
Following successful completion of Phase 1 trials, experimental therapies often advance into one or more Phase 2 trials to evaluate the efficacy and safety of a candidate in the target patient population. Goals for Phase 2 trials may include selecting an optimal dose or dosing regimen, identifying specific patient group who may respond to medication more or less favorably, and assessing the safety and tolerability profile. Meetings with the U.S. Food and Drug Administration and other countries’ regulatory authorities are held following the conclusion of Phase 2 clinical trials to review data before proceeding into the next phase of development.
Phase 3 trials are the final step in a product’s clinical develop and are designed to test the optimal dose or dosing regimen in a large number of people with a specific disease or condition. They aim to enroll people with diversity in race, gender, geography, and socioeconomic status to mirror the conditions in which a candidate might be used in the future when it’s broadly available.
Because these studies involve experimental treatments, all clinical trials are closely monitored by regulatory authorities as well as independent ethics committees (IECs) or institutional review boards (IRBs) to ensure that any safety issues that arise are carefully documented.
Expanded Access Policy
We are a clinical stage biopharmaceutical company engaged in the development of small-molecule therapeutics targeting age-related degenerative diseases. We currently have several clinical studies planned or underway that are designed to measure safety and efficacy outcomes of our experimental medications for patients with Alzheimer’s disease, GA secondary to dry age-related macular degeneration and dementia with Lewy bodies.
At this time, we do not offer expanded access to any of our therapies in development. Rather, before our drug candidates complete their clinical development and are reviewed and approved by regulatory authorities, they can only be accessed through participation in our clinical trials.